Adial Pharmaceuticals Inc (ADIL) - Total Assets
Based on the latest financial reports, Adial Pharmaceuticals Inc (ADIL) holds total assets worth $5.23 Million USD as of March 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Adial Pharmaceuticals Inc - Total Assets Trend (2015–2025)
This chart illustrates how Adial Pharmaceuticals Inc's total assets have evolved over time, based on quarterly financial data. Also see ADIL company net worth for the company's overall valuation and market capitalisation.
Adial Pharmaceuticals Inc - Asset Composition Analysis
Current Asset Composition (December 2025)
Adial Pharmaceuticals Inc's total assets of $5.23 Million consist of 90.9% current assets and 9.1% non-current assets. Review ADIL liabilities breakdown to assess the company's total debt and financial obligations.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 86.5% |
| Accounts Receivable | $41.76K | 0.6% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $2.78K | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2015–2025)
This chart illustrates how Adial Pharmaceuticals Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. See ADIL share price today for real-time trading data and today's change.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Adial Pharmaceuticals Inc's current assets represent 90.9% of total assets in 2025, a decrease from 95.1% in 2015.
- Cash Position: Cash and equivalents constituted 86.5% of total assets in 2025, up from 75.1% in 2015.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, a decrease from 3.0% in 2015.
- Asset Diversification: The largest asset category is accounts receivable at 0.6% of total assets.
Adial Pharmaceuticals Inc Competitors by Total Assets
Key competitors of Adial Pharmaceuticals Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
ALK-Abelló A/S
CO:ALK-B
|
Denmark | Dkr9.17 Billion |
|
Mirum Pharmaceuticals Inc
NASDAQ:MIRM
|
USA | $890.92 Million |
|
Xiamen Amoytop Biotech Co Ltd
SHG:688278
|
China | CN¥3.21 Billion |
|
BB Biotech AG
SW:BION
|
Switzerland | CHF3.09 Billion |
|
Soleno Therapeutics Inc
NASDAQ:SLNO
|
USA | $608.39 Million |
|
Nanobiotix
NASDAQ:NBTX
|
USA | $67.76 Million |
|
Inhibrx Biosciences, Inc.
NASDAQ:INBX
|
USA | $183.97 Million |
|
Wuhan Keqian Biology Co Ltd
SHG:688526
|
China | CN¥4.75 Billion |
Adial Pharmaceuticals Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 3.18 | 1.99 | 2.53 |
| Quick Ratio | 3.18 | 1.99 | 2.53 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $3.29 Million | $1.30 Million | $3.38 Million |
Adial Pharmaceuticals Inc - Advanced Valuation Insights
This section examines the relationship between Adial Pharmaceuticals Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 2.48 |
| Latest Market Cap to Assets Ratio | 1.39 |
| Asset Growth Rate (YoY) | 34.8% |
| Total Assets | $6.80 Million |
| Market Capitalization | $9.43 Million USD |
Valuation Analysis
Above Book Valuation: The market values Adial Pharmaceuticals Inc's assets above their book value (1.39x), reflecting positive investor sentiment about the company's future prospects.
Rapid Asset Growth: Adial Pharmaceuticals Inc's assets grew by 34.8% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Adial Pharmaceuticals Inc (2015–2025)
The table below shows the annual total assets of Adial Pharmaceuticals Inc from 2015 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | $6.80 Million | +34.78% |
| 2024-12-31 | $5.04 Million | +6.48% |
| 2023-12-31 | $4.74 Million | -17.37% |
| 2022-12-31 | $5.73 Million | -24.90% |
| 2021-12-31 | $7.63 Million | +39.01% |
| 2020-12-31 | $5.49 Million | -28.49% |
| 2019-12-31 | $7.68 Million | +63.42% |
| 2018-12-31 | $4.70 Million | +13502.98% |
| 2017-12-31 | $34.55K | -77.20% |
| 2016-12-31 | $151.53K | -29.92% |
| 2015-12-31 | $216.22K | -- |
About Adial Pharmaceuticals Inc
Adial Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment or prevention of addiction and related disorders. The company's lead product is AD04, a serotonin-3 antagonist, which is in Phase 3 clinical trials for the treatment of alcohol use disorder. It is also involved in the development of drug candidates for non-opioid p… Read more